The global pharmaceutical contract manufacturing market size is calculated at USD 194.54 billion in 2025 and is forecasted to reach around USD 351.55 billion by 2034, accelerating at a CAGR of 6.76% from 2025 to 2034. The North America pharmaceutical contract manufacturing market size surpassed USD 65.82 billion in 2024 and is expanding at a CAGR of 6.80% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical Contract Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical Contract Manufacturing Market, by Service
8.1.1. Pharmaceutical Manufacturing Services
8.1.1.1. Market Revenue and Forecast
8.1.2. Pharmaceutical API Manufacturing Services
8.1.2.1. Market Revenue and Forecast
8.1.3. Pharmaceutical FDF Manufacturing Services
8.1.3.1. Market Revenue and Forecast
8.1.4. Drug Development Services
8.1.4.1. Market Revenue and Forecast
8.1.5. Biologic Manufacturing Services
8.1.5.1. Market Revenue and Forecast
8.1.6. Biologic API Manufacturing Services
8.1.6.1. Market Revenue and Forecast
8.1.7. Biologic FDF Manufacturing Services
8.1.7.1. Market Revenue and Forecast
9.1. Pharmaceutical Contract Manufacturing Market, by End User
9.1.1. Big Pharmaceutical Companies
9.1.1.1. Market Revenue and Forecast
9.1.2. Small & Mid-Sized Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast
9.1.3. Generic Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast
9.1.4. Other End Users (Academic Institutes, Small CDMOs, and CROs)
9.1.4.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Service
10.1.2. Market Revenue and Forecast, by End User
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service
10.1.3.2. Market Revenue and Forecast, by End User
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service
10.1.4.2. Market Revenue and Forecast, by End User
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service
10.2.2. Market Revenue and Forecast, by End User
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service
10.2.3.2. Market Revenue and Forecast, by End User
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service
10.2.4.2. Market Revenue and Forecast, by End User
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service
10.2.5.2. Market Revenue and Forecast, by End User
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service
10.2.6.2. Market Revenue and Forecast, by End User
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service
10.3.2. Market Revenue and Forecast, by End User
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service
10.3.3.2. Market Revenue and Forecast, by End User
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service
10.3.4.2. Market Revenue and Forecast, by End User
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service
10.3.5.2. Market Revenue and Forecast, by End User
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service
10.3.6.2. Market Revenue and Forecast, by End User
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service
10.4.2. Market Revenue and Forecast, by End User
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service
10.4.3.2. Market Revenue and Forecast, by End User
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service
10.4.4.2. Market Revenue and Forecast, by End User
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service
10.4.5.2. Market Revenue and Forecast, by End User
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service
10.4.6.2. Market Revenue and Forecast, by End User
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service
10.5.2. Market Revenue and Forecast, by End User
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service
10.5.3.2. Market Revenue and Forecast, by End User
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service
10.5.4.2. Market Revenue and Forecast, by End User
11.1. Lonza Group
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Catalent, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Patheon (Now part of Thermo Fisher Scientific)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Recipharm AB
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Boehringer Ingelheim
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Dr. Reddy's Laboratories
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Jubilant Life Sciences
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Fareva
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Vetter Pharma
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Evonik Industries
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample